{"id":11377,"date":"2022-07-01T20:35:02","date_gmt":"2022-07-02T00:35:02","guid":{"rendered":"https:\/\/www.cancerresearch.org\/event\/2018-asco-meeting\/"},"modified":"2022-07-14T13:30:53","modified_gmt":"2022-07-14T17:30:53","slug":"2018-asco-meeting","status":"publish","type":"cri_events","link":"https:\/\/www.cancerresearch.org\/es\/events\/2018-asco-meeting","title":{"rendered":"2018 ASCO Meeting"},"content":{"rendered":"<p>The Annual Meeting of the American Society of Clinical Oncologists brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.<\/p>\n<p>CRI scientists are presenting at the meeting. We are providing&nbsp;a <a href=\"https:\/\/www.cancerresearch.org\/blog?c=226\">daily recap of new work<\/a> coming out of the conference, and we are <a href=\"https:\/\/www.cancerresearch.org\/cancer-immunotherapy-month\/asco-news-2018-oncologist-panel-video-for-patients\">hosting a conference panel<\/a> with experts translating this new research into what this means for patients.&nbsp;<\/p>\n<p>Below are some of the CRI scientists who are, either in person or represented through their work, at ASCO18:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/georgina-venetia-long-md-phd\">Georgina V. Long, MD<\/a>, PhD, a CRI Clinical Team Leader at the Melanoma Institute Australia, is giving a <a href=\"https:\/\/meetinglibrary.asco.org\/record\/164607\/abstract\">talk<\/a> on a phase III trial comparing anti-PD-1 checkpoint immunotherapy alone versus in combination with an IDO1 inhibitor in patients with unresectable or metastatic melanoma. Long is giving another <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159075\/abstract\">talk<\/a> on the long-term benefits of anti-PD-1 checkpoint immunotherapy for melanoma patients that is determining how the duration of treatment affects outcomes. Long is also involved in two other projects being highlighted: <a href=\"file:\/\/\/C:UsersabrodskyDesktop(positron%20emission%20tomography)\">one<\/a> that is utilizing PET (positron emission tomography) scans to determine patient outcomes after anti-PD-1 checkpoint immunotherapy, and <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159094\/abstract\">another<\/a> that is exploring biomarkers associated with responses to anti-PD-1 checkpoint immunotherapy given alone as well as in combination.<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/antoni-ribas-md-phd\">Antoni Ribas, MD, PhD<\/a>, a leader of the CRI-SU2C Dream Team at the University of California, Los Angeles (UCLA), and a member of the <a href=\"\/scientists\/clinical-accelerator\/leadership\">CRI Clinical Accelerator Leadership<\/a>, is leading <a href=\"https:\/\/meetinglibrary.asco.org\/record\/161517\/abstract\">work<\/a> in which patients with advanced melanoma are treated with the combination of an anti-PD-1 checkpoint inhibitor and a Toll-like receptor 9 (TLR9) agonist. Ribas is also leading <a href=\"https:\/\/meetinglibrary.asco.org\/record\/161673\/abstract\">work<\/a> looking at long-term benefits of patients with advanced melanoma who were treated with anti-PD-1 checkpoint immunotherapy.<\/li>\n<li>Margaret Callahan, MD, PhD, a former CRI postdoctoral fellow at Memorial Sloan Kettering Cancer Center, is leading <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159148\/abstract\">work<\/a> involving the combination of an anti-PD-1 checkpoint inhibitor and an ICOS agonist in patients with several types of advanced cancer.<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/hideho-okada,-m-d-,-ph-d\">Hideho Okada, MD, PhD<\/a>, a CRI&nbsp;Clinical Team Leader at the University of California, San Francisco (UCSF), is involved in <a href=\"https:\/\/meetinglibrary.asco.org\/record\/163137\/abstract\">work<\/a> that developed personalized vaccines for patients with newly diagnosed <a href=\"https:\/\/www.cancerresearch.org\/cancer-types\/brain-cancer\">glioblastoma<\/a>.<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/scientific-advisory-council\/james-allison\/\">James P. Allison, PhD<\/a>, and <a href=\"https:\/\/www.cancerresearch.org\/stories\/scientists\/padmanee-sharma,-m-d-,-ph-d\">Padmanee Sharma, MD, PhD<\/a>, both of the University of Texas MD Anderson Cancer Center, are involved in work that evaluating the effectiveness of an anti-PD-1 checkpoint inhibitor both before and after surgery in patients with recurrent glioblastoma, a type of brain cancer. Allison is the director of <a href=\"https:\/\/www.cancerresearch.org\/our-impact\/scientific-leadership\">CRI&rsquo;s Scientific Advisory Council<\/a> as well as a leader of the CRI-SU2C Dream Team, of which Sharma is also a member.<\/li>\n<li>Suzanne Topalian, MD, PhD, a member of the CRI-SU2C Dream Team at the Johns Hopkins University School of Medicine, is giving a <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159078\/abstract\">talk<\/a> on the benefits of anti-PD-1 checkpoint immunotherapy prior to surgery in patients with resectable Merkel cell carcinoma.<\/li>\n<li>Jhanelle Gray, MD, of Moffitt Cancer Center, is leading a discussion about insights regarding patient reported outcomes (PROs) in first-line combination immunotherapy trials in advanced lung cancer. Gray is also involved in a lung cancer immunotherapy trial sponsored by the <a href=\"\/scientistshttps:\/\/www.cancerresearch.org\/clinical-accelerator\">CRI Clinical Accelerator<\/a>.<\/li>\n<li>Israel Lowy, MD, PhD, of Regeneron, and a member of the steering committee of CRI&rsquo;s <a href=\"\/scientists\/cancer-immunotherapy-consortium\">Cancer Immunotherapy Consortium<\/a>, is involved in <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159083\/abstract\">work<\/a> exploring the effectiveness of anti-PD-1 checkpoint immunotherapy in patients with metastatic squamous cell carcinoma.<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/scientific-advisory-council\/thomas-gajewski\">Thomas Gajewski, MD, PhD<\/a>, a former CRI CLIP Investigator at the University of Chicago Medical Center and current member of the <a href=\"https:\/\/www.cancerresearch.org\/our-impact\/scientific-leadership\">CRI Scientific Advisory Council<\/a>, is discussing three separate projects: <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159155\/abstract\">one<\/a> focusing on an immune-related biomarker that could predict outcomes to anti-PD-1\/PD-L1 checkpoint immunotherapy, <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159160\/abstract\">another<\/a> dealing with using machine learning algorithms to determine factors important for effective immunotherapy, and <a href=\"https:\/\/meetinglibrary.asco.org\/record\/159151\/abstract\">one<\/a> investigating how different forms of progressive disease are associated with different outcomes.&nbsp;<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/stories\/scientists\/david-reardon,-m-d\">David Reardon, MD<\/a>, of the Dana-Farber Cancer Institute, is speaking about <a href=\"https:\/\/meetinglibrary.asco.org\/record\/162652\/abstract\">work<\/a> that involved the combination of an anti-PD-1 checkpoint inhibitor and an anti-VEGF-A targeted antibody to treat patients with recurrent glioblastoma, a type of brain cancer. Reardon is also currently leading a brain cancer clinical trial sponsored by CRI&rsquo;s <a href=\"https:\/\/www.cancerresearch.org\/clinical-accelerator\/leadership\/scientific-advisory-committee\/e-john-wherry\">Clinical Accelerator<\/a>.<\/li>\n<li><a href=\"https:\/\/www.cancerresearch.org\/scientific-advisory-council\/charles-g-drake\">Charles G. Drake, MD, PhD<\/a>, of New York-Presbyterian and the Columbia University Medical Center and a CRI Scientific Advisory Council member, is <a href=\"https:\/\/meetinglibrary.asco.org\/record\/162284\/video\">discussing<\/a> the topic of combination immunotherapies and whether they have come of age.<\/li>\n<\/ul>\n<p>For more on ASCO18, be sure to check out our daily blog coverage (<a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-day-1-vaccines-car-t-cells-ox40\">Day 1<\/a>, <a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-day-2-combination-therapies-immune-system\">Day 2<\/a>, <a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-day-3-immunotherapy-lung-ovarian-cancer\">Day 3<\/a>, <a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-day-4-melanoma-lung-cancer\">Day 4<\/a>, <a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-day-5-biomarkers-improve-immunotherapy\">Day 5<\/a>) and our overall <a href=\"https:\/\/www.cancerresearch.org\/blog\/june-2018\/asco18-recap-immunotherapy-revolutionizing-cancer\">recap<\/a>.<\/p>\n<p><em>Banner image: Willis Tower Skydeck, Chicago, United States.&nbsp;Photo by&nbsp;Pedro Lastra&nbsp;on&nbsp;Unsplash.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CRI scientists present&nbsp;at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides&nbsp;a daily recap of new work coming out of the conference.&nbsp;<\/p>\n","protected":false},"featured_media":1131,"template":"","events_categories":[203],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11377","cri_events","type-cri_events","status-publish","has-post-thumbnail","hentry","events_categories-cri-speaks"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2018 ASCO Meeting - Cancer Research Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2018 ASCO Meeting - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"CRI scientists present&nbsp;at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides&nbsp;a daily recap of new work coming out of the conference.&nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-14T17:30:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting\",\"url\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting\",\"name\":\"2018 ASCO Meeting - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png\",\"datePublished\":\"2022-07-02T00:35:02+00:00\",\"dateModified\":\"2022-07-14T17:30:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png\",\"width\":800,\"height\":420},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Event\",\"item\":\"https:\/\/www.cancerresearch.org\/events\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"2018 ASCO Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2018 ASCO Meeting - Cancer Research Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting","og_locale":"es_ES","og_type":"article","og_title":"2018 ASCO Meeting - Cancer Research Institute","og_description":"CRI scientists present&nbsp;at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides&nbsp;a daily recap of new work coming out of the conference.&nbsp;","og_url":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-14T17:30:53+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting","url":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting","name":"2018 ASCO Meeting - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png","datePublished":"2022-07-02T00:35:02+00:00","dateModified":"2022-07-14T17:30:53+00:00","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/7c5491e1-5176-4d60-93a7-4ba2fd6e9230.png","width":800,"height":420},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/events\/2018-asco-meeting#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Event","item":"https:\/\/www.cancerresearch.org\/events"},{"@type":"ListItem","position":3,"name":"2018 ASCO Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events\/11377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_events"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/1131"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11377"}],"wp:term":[{"taxonomy":"events_categories","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/events_categories?post=11377"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11377"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11377"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11377"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11377"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}